ArticleHuman vaccines & immunotherapeutics2014
Protecting a new generation against HPV: are we willing to be bold?
Article in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A randomized, controlled, pragmatic trial of an iPad-based, tailored messaging intervention to increase human papillomavirus vaccination among Latinos.Human vaccines & immunotherapeutics · 2019Trial
- Human Papillomavirus Awareness, Vaccine Status, and Risk Factors in Female Emergency Patients.The western journal of emergency medicine · 2020Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
Despite the advent of a novel human papillomavirus (HPV) vaccine to prevent associated cancers, HPV vaccination rates in the United States (US) remain well below national goals. Two recent reports by the Centers for Disease Control and Prevention (CDC) and the President's Cancer Panel (PCP) have identified missed clinical opportunities as an intervention point for increasing HPV vaccination rates, including the provision of immunization in alternative venues by varying healthcare providers. In this paper, we specifically comment on the idea of offering HPV vaccination in emergency departments (ED) by emergency medicine (EM) physicians as posited by Hill and Okugo (2014), identifying both strengths and limitations to this strategy. We also offer ideas for additional research, suggest provider and healthcare systems changes, and discuss needed policy changes to improve HPV vaccination rates in the US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.